HealthTech 250 - The Most Promising Early-Stage Digital Health Ventures of 2022

Since 2017, Galen Growth has tracked and reported on the Digital Health innovation across the globe. HealthTech Alpha’s unmatched data, intel and insights allow us to uniquely assess, identify and showcase the most promising early stage Digital Health ventures in the world. Leveraging over 250 million data points and our proprietary venture signals analytics, we are proud to announce our HealthTech 250 - The Most Promising Early Stage Digital Health Ventures in 2022 and to share with you our data and analysis on each venture.

Last Updated: November 28, 2022

Ventures

Venture	Primary Category	Country	Therapeutic Focus	Valuation	Stage	Current Funding
1E Therapeutics (אחד אי תרפיוטיקס בע"מ)	Drug Discovery	Israel	$ 123.46 B	$ 123.46 B	Seed	$ 120.00 M
52North	Omics Related Diagnosis	United Kingdom	$ 123.46 B	$ 123.46 B	Grant	$ 0.05 M
9amHealth	Disease Management	United States	$ 123.46 B	$ 123.46 B	Series A1	$ 9.50 M
AbCellera	Drug Discovery	Canada	$ 123.46 B	$ 123.46 B	Grant	$ 2.09 M
Abridge	Physician / Clinic	United States	$ 123.46 B	$ 123.46 B	Series C	$ 150.00 M
Abtrace	Diagnosis Tools	United Kingdom	$ 123.46 B	$ 123.46 B	Grant	$ 0.44 M
ACCELStars (ACCELStars)	Wearables	Japan	$ 123.46 B	$ 123.46 B	Strategic	undisclosed
accessiBe(אקססיבי בע~מ)	Assistive Care	Israel	$ 123.46 B	$ 123.46 B	Series A2	$ 30.00 M
Aesop Technology (醫守科技)	Prescriptive Analytics	United States	$ 123.46 B	$ 123.46 B	Pre-A	$ 2.95 M
AEYE Health(איי.אי.וואי.אי בריאות בע~מ)	Diagnosis Tools	Israel	$ 123.46 B	$ 123.46 B	Seed	$ 5.70 M

Showing 1 to 10 of 250 entries